RYBREVANT® and LAZCLUZE® Show Promising Results in Advanced NSCLC Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 46 minutes ago
0mins
Source: PRnewswire
- Significant Survival Improvement: In the CHRYSALIS-2 study, the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of 3.5 years in patients, significantly surpassing the two-year survival with current standard treatments, indicating the potential of this combination in difficult-to-treat non-small cell lung cancer (NSCLC) patients.
- Addressing Unmet Needs: Approximately 10-20% of EGFR mutation patients have atypical mutations, with limited effective first-line treatment options available; the dual-targeting mechanism of RYBREVANT® may provide more durable treatment outcomes for these patients, potentially reshaping treatment strategies.
- Consistent Clinical Activity: The clinical activity of RYBREVANT® plus LAZCLUZE® remained consistent across various atypical EGFR mutation subgroups, with 41% of patients continuing treatment after two years, further supporting the combination's tolerability and effectiveness.
- Favorable Safety Profile: The safety of RYBREVANT® and LAZCLUZE® combination therapy was consistent with previous reports, with most adverse events being Grade 1 or 2, and no new safety signals observed, ensuring patient safety during long-term treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 230.800
Low
190.00
Averages
218.50
High
240.00
Current: 230.800
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson's Lung Cancer Therapy Shows Significant Survival Improvement
- Survival Rate Data: Johnson & Johnson's RYBREVANT-LAZCLUZE combination therapy achieved a median overall survival of nearly 3.5 years in 49 patients with advanced lung cancer carrying atypical EGFR mutations, indicating the therapy's potential in treating this patient group.
- Study Results Presentation: The findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; however, despite the positive data, JNJ's stock fell 2.3% during Friday trading, reflecting market caution regarding the new therapy's reception.
- Long-term Survival Rates: The data showed that 55% of patients treated with the combination were alive after three years and 46% after four years, suggesting the therapy's potential for durable disease control, which could influence future treatment decisions.
- Market Sentiment Shift: Stocktwits sentiment on JNJ improved from “neutral” to “bullish,” indicating investor optimism about the therapy's prospects, with the stock gaining over 47% in the past 12 months.
See More
RYBREVANT® and LAZCLUZE® Show Promising Results in Advanced NSCLC Treatment
- Significant Survival Improvement: In the CHRYSALIS-2 study, the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of 3.5 years in patients, significantly surpassing the two-year survival with current standard treatments, indicating the potential of this combination in difficult-to-treat non-small cell lung cancer (NSCLC) patients.
- Addressing Unmet Needs: Approximately 10-20% of EGFR mutation patients have atypical mutations, with limited effective first-line treatment options available; the dual-targeting mechanism of RYBREVANT® may provide more durable treatment outcomes for these patients, potentially reshaping treatment strategies.
- Consistent Clinical Activity: The clinical activity of RYBREVANT® plus LAZCLUZE® remained consistent across various atypical EGFR mutation subgroups, with 41% of patients continuing treatment after two years, further supporting the combination's tolerability and effectiveness.
- Favorable Safety Profile: The safety of RYBREVANT® and LAZCLUZE® combination therapy was consistent with previous reports, with most adverse events being Grade 1 or 2, and no new safety signals observed, ensuring patient safety during long-term treatment.
See More
Johnson & Johnson's RYBREVANT® and LAZCLUZE® Combination Significantly Improves Survival in NSCLC Patients
- Survival Rate Improvement: The CHRYSALIS-2 study demonstrated that the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC), indicating significant long-term efficacy in this difficult-to-treat population and potentially altering treatment paradigms.
- Objective Response Rate: The study reported a primary endpoint of a 57% objective response rate for the combination therapy, highlighting its substantial clinical activity in patients with atypical EGFR mutations and addressing the urgent market need for effective treatment options.
- Good Patient Tolerance: Among treated patients, 41% remained on RYBREVANT® for two years or longer, suggesting excellent tolerability of the treatment regimen, which may provide patients with more durable disease control.
- Significant Clinical Implications: The use of RYBREVANT® in combination with LAZCLUZE® not only targets common EGFR mutations but also extends to atypical mutations, filling a critical gap in current treatment options and indicating broad future application potential in lung cancer therapy.
See More
Johnson & Johnson's RYBREVANT® and LAZCLUZE® Show Promising Results in Non-Small Cell Lung Cancer Study
- Significant Survival Extension: In the CHRYSALIS-2 study, the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of nearly 3.5 years (41.0 months), significantly surpassing the two-year survival of current standard treatments, indicating a potential advantage for this regimen in difficult-to-treat EGFR-mutated patients.
- Consistent Clinical Responses: The study demonstrated consistent clinical responses across various atypical EGFR mutation subgroups, with a 57% objective response rate further supporting the efficacy of this combination in first-line treatment, potentially altering clinical treatment strategies.
- Long-term Treatment Tolerance: Notably, 41% of patients remained on RYBREVANT® for two years or longer, indicating good tolerability and durable efficacy of the treatment regimen, which may provide patients with extended survival and improved quality of life.
- Market Demand and Strategic Implications: Patients with atypical EGFR mutations in NSCLC face significant treatment needs, and the successful application of RYBREVANT® and LAZCLUZE® not only fills this market gap but also may enhance Johnson & Johnson's leadership position in lung cancer treatment.
See More
Regulatory Approvals and Collaborations in Biotech Sector
- FDA Approval for AZN: AstraZeneca (AZN) secured FDA approval for the IMFINZI + BCG combination in high-risk non-muscle-invasive bladder cancer, supported by Phase 3 POTOMAC data showing a 32% reduction in recurrence or death, enhancing its competitive edge in oncology.
- JNJ TREMFYA Label Expansion: Johnson & Johnson (JNJ) received FDA approval to add structural joint-damage inhibition data to the TREMFYA label for active psoriatic arthritis, confirming its unique position in first-line treatment with no new safety signals, reinforcing its market leadership.
- LINZESS Approved for Children: Ironwood Pharmaceuticals (IRWD) gained FDA approval for LINZESS to treat functional constipation in children aged 2-5, based on a 12-week Phase 3 trial showing significant improvement in spontaneous bowel movements, expanding its pediatric market influence.
- AbbVie's DECNUPAZ Approval: AbbVie (ABBV) received FDA approval for DECNUPAZ to treat ultra-rare blood cancer BPDCN, supported by Phase 1 data showing a 69.7% composite complete response rate and a median duration of 9.7 months, marking a significant innovation in hematologic oncology.
See More
Johnson & Johnson Reports Positive Phase 3 Results for TECVAYLI in Multiple Myeloma
- Clinical Trial Success: Johnson & Johnson's MajesTEC-9 study demonstrated that TECVAYLI reduced the risk of disease progression or death by 71% and lowered the risk of death by 40% in patients with relapsed or refractory multiple myeloma, indicating a significant therapeutic advantage over standard care.
- Significant Patient Response: Nearly two-thirds of patients treated with TECVAYLI achieved a complete response or better, compared to only 16.8% of those receiving standard treatment, highlighting TECVAYLI's potential to redefine treatment standards in this patient population.
- Consistent Safety Profile: The safety profile of TECVAYLI was consistent with previous findings, with treatment-emergent adverse events similar to those seen with standard therapies, indicating its acceptability and safety in clinical applications.
- Regulatory Application Progress: Johnson & Johnson is collaborating with global regulators to expand the use of TECVAYLI as a second-line treatment, having already submitted applications to the U.S. FDA and the European Medicines Agency, signaling strong market potential and future growth opportunities.
See More
Johnson & Johnson's Lung Cancer Therapy Shows Significant Survival Improvement
- Survival Rate Data: Johnson & Johnson's RYBREVANT-LAZCLUZE combination therapy achieved a median overall survival of nearly 3.5 years in 49 patients with advanced lung cancer carrying atypical EGFR mutations, indicating the therapy's potential in treating this patient group.
- Study Results Presentation: The findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting; however, despite the positive data, JNJ's stock fell 2.3% during Friday trading, reflecting market caution regarding the new therapy's reception.
- Long-term Survival Rates: The data showed that 55% of patients treated with the combination were alive after three years and 46% after four years, suggesting the therapy's potential for durable disease control, which could influence future treatment decisions.
- Market Sentiment Shift: Stocktwits sentiment on JNJ improved from “neutral” to “bullish,” indicating investor optimism about the therapy's prospects, with the stock gaining over 47% in the past 12 months.
See More
RYBREVANT® and LAZCLUZE® Show Promising Results in Advanced NSCLC Treatment
- Significant Survival Improvement: In the CHRYSALIS-2 study, the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of 3.5 years in patients, significantly surpassing the two-year survival with current standard treatments, indicating the potential of this combination in difficult-to-treat non-small cell lung cancer (NSCLC) patients.
- Addressing Unmet Needs: Approximately 10-20% of EGFR mutation patients have atypical mutations, with limited effective first-line treatment options available; the dual-targeting mechanism of RYBREVANT® may provide more durable treatment outcomes for these patients, potentially reshaping treatment strategies.
- Consistent Clinical Activity: The clinical activity of RYBREVANT® plus LAZCLUZE® remained consistent across various atypical EGFR mutation subgroups, with 41% of patients continuing treatment after two years, further supporting the combination's tolerability and effectiveness.
- Favorable Safety Profile: The safety of RYBREVANT® and LAZCLUZE® combination therapy was consistent with previous reports, with most adverse events being Grade 1 or 2, and no new safety signals observed, ensuring patient safety during long-term treatment.
See More
Johnson & Johnson's RYBREVANT® and LAZCLUZE® Combination Significantly Improves Survival in NSCLC Patients
- Survival Rate Improvement: The CHRYSALIS-2 study demonstrated that the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of nearly 3.5 years in patients with advanced non-small cell lung cancer (NSCLC), indicating significant long-term efficacy in this difficult-to-treat population and potentially altering treatment paradigms.
- Objective Response Rate: The study reported a primary endpoint of a 57% objective response rate for the combination therapy, highlighting its substantial clinical activity in patients with atypical EGFR mutations and addressing the urgent market need for effective treatment options.
- Good Patient Tolerance: Among treated patients, 41% remained on RYBREVANT® for two years or longer, suggesting excellent tolerability of the treatment regimen, which may provide patients with more durable disease control.
- Significant Clinical Implications: The use of RYBREVANT® in combination with LAZCLUZE® not only targets common EGFR mutations but also extends to atypical mutations, filling a critical gap in current treatment options and indicating broad future application potential in lung cancer therapy.
See More
Johnson & Johnson's RYBREVANT® and LAZCLUZE® Show Promising Results in Non-Small Cell Lung Cancer Study
- Significant Survival Extension: In the CHRYSALIS-2 study, the combination of RYBREVANT® and LAZCLUZE® achieved a median overall survival of nearly 3.5 years (41.0 months), significantly surpassing the two-year survival of current standard treatments, indicating a potential advantage for this regimen in difficult-to-treat EGFR-mutated patients.
- Consistent Clinical Responses: The study demonstrated consistent clinical responses across various atypical EGFR mutation subgroups, with a 57% objective response rate further supporting the efficacy of this combination in first-line treatment, potentially altering clinical treatment strategies.
- Long-term Treatment Tolerance: Notably, 41% of patients remained on RYBREVANT® for two years or longer, indicating good tolerability and durable efficacy of the treatment regimen, which may provide patients with extended survival and improved quality of life.
- Market Demand and Strategic Implications: Patients with atypical EGFR mutations in NSCLC face significant treatment needs, and the successful application of RYBREVANT® and LAZCLUZE® not only fills this market gap but also may enhance Johnson & Johnson's leadership position in lung cancer treatment.
See More
Regulatory Approvals and Collaborations in Biotech Sector
- FDA Approval for AZN: AstraZeneca (AZN) secured FDA approval for the IMFINZI + BCG combination in high-risk non-muscle-invasive bladder cancer, supported by Phase 3 POTOMAC data showing a 32% reduction in recurrence or death, enhancing its competitive edge in oncology.
- JNJ TREMFYA Label Expansion: Johnson & Johnson (JNJ) received FDA approval to add structural joint-damage inhibition data to the TREMFYA label for active psoriatic arthritis, confirming its unique position in first-line treatment with no new safety signals, reinforcing its market leadership.
- LINZESS Approved for Children: Ironwood Pharmaceuticals (IRWD) gained FDA approval for LINZESS to treat functional constipation in children aged 2-5, based on a 12-week Phase 3 trial showing significant improvement in spontaneous bowel movements, expanding its pediatric market influence.
- AbbVie's DECNUPAZ Approval: AbbVie (ABBV) received FDA approval for DECNUPAZ to treat ultra-rare blood cancer BPDCN, supported by Phase 1 data showing a 69.7% composite complete response rate and a median duration of 9.7 months, marking a significant innovation in hematologic oncology.
See More
Johnson & Johnson Reports Positive Phase 3 Results for TECVAYLI in Multiple Myeloma
- Clinical Trial Success: Johnson & Johnson's MajesTEC-9 study demonstrated that TECVAYLI reduced the risk of disease progression or death by 71% and lowered the risk of death by 40% in patients with relapsed or refractory multiple myeloma, indicating a significant therapeutic advantage over standard care.
- Significant Patient Response: Nearly two-thirds of patients treated with TECVAYLI achieved a complete response or better, compared to only 16.8% of those receiving standard treatment, highlighting TECVAYLI's potential to redefine treatment standards in this patient population.
- Consistent Safety Profile: The safety profile of TECVAYLI was consistent with previous findings, with treatment-emergent adverse events similar to those seen with standard therapies, indicating its acceptability and safety in clinical applications.
- Regulatory Application Progress: Johnson & Johnson is collaborating with global regulators to expand the use of TECVAYLI as a second-line treatment, having already submitted applications to the U.S. FDA and the European Medicines Agency, signaling strong market potential and future growth opportunities.
See More
